The Business Model of Insilico Medicine

As of August 26, 2026

Insilico Medicine is a global, clinical-stage biotechnology company that applies generative artificial intelligence and automation across drug discovery and development. Its proprietary Pharma.AI platform supports target identification, small-molecule design and clinical-development analysis.

Founded in 2014 by Alex Zhavoronkov, the company develops an internal pipeline of drug candidates and works with pharmaceutical and biotechnology partners. The group reported 317 employees and consultants as of December 31, 2025, and its official materials identify headquarters in Boston and Hong Kong.

2014

Founded

317

Employees

Boston, MA

Headquarter

Hard Facts

Business Model Canvas

This canvas shows a detailed explanation of how the business model of Insilico Medicine is structured.

Unlock Premium Content

Get full access to 500+ Business Model Analyzes with Premium and discover the full scope!

Business Model Patterns

The business model patterns of Insilico Medicine help to understand the mechanics behind the business model. Furthermore you can learn more about the specific business model pattern by clicking learn more.

Unlock Premium Content

Get full access to 500+ Business Model Analyzes with Premium and discover the full scope!

SWOT Analysis

The SWOT Analysis of Insilico Medicine is about the strengths, weaknesses, opportunities and threats of the companies business model. By clicking the i you can see a detailed description.

Unlock Premium Content

Get full access to 500+ Business Model Analyzes with Premium and discover the full scope!

What makes Insilico Medicine special?

This section is all about the secret sauce of the business model of Insilico Medicine. If there is any incredible information about the founding team (like how they started the business, etc.) you can learn from you can find it here!